JP2025509404A - Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体 - Google Patents

Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体 Download PDF

Info

Publication number
JP2025509404A
JP2025509404A JP2024553774A JP2024553774A JP2025509404A JP 2025509404 A JP2025509404 A JP 2025509404A JP 2024553774 A JP2024553774 A JP 2024553774A JP 2024553774 A JP2024553774 A JP 2024553774A JP 2025509404 A JP2025509404 A JP 2025509404A
Authority
JP
Japan
Prior art keywords
methyl
pentyl
butyl
hexyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509404A5 (cg-RX-API-DMAC10.html
Inventor
シュウ、サンジア
リー、ジン
ワン、ジウェイ
Original Assignee
ベイジーン スイッツァランド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジーン スイッツァランド ゲーエムベーハー filed Critical ベイジーン スイッツァランド ゲーエムベーハー
Publication of JP2025509404A publication Critical patent/JP2025509404A/ja
Publication of JP2025509404A5 publication Critical patent/JP2025509404A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024553774A 2022-03-15 2023-03-14 Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体 Pending JP2025509404A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022080837 2022-03-15
CNPCT/CN2022/080837 2022-03-15
PCT/CN2023/081281 WO2023174250A1 (en) 2022-03-15 2023-03-14 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5

Publications (2)

Publication Number Publication Date
JP2025509404A true JP2025509404A (ja) 2025-04-11
JP2025509404A5 JP2025509404A5 (cg-RX-API-DMAC10.html) 2026-03-18

Family

ID=88022264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553774A Pending JP2025509404A (ja) 2022-03-15 2023-03-14 Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体

Country Status (5)

Country Link
US (1) US20250000854A1 (cg-RX-API-DMAC10.html)
EP (1) EP4493555A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025509404A (cg-RX-API-DMAC10.html)
CN (1) CN118871432A (cg-RX-API-DMAC10.html)
WO (1) WO2023174250A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4574816A4 (en) * 2022-07-07 2026-01-14 Xizang Haisco Pharmaceutical Co Ltd HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND ITS USE
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2025031468A1 (zh) 2023-08-09 2025-02-13 江苏恒瑞医药股份有限公司 杂芳基化合物、其制备方法及其在医药上的应用
CN121159457B (zh) * 2025-11-20 2026-03-17 英矽智能科技(上海)有限公司 Prmt5抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075783A2 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
MX2015006780A (es) * 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
GB201604027D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
CN120208880A (zh) * 2019-09-12 2025-06-27 米拉蒂医疗股份有限公司 Mta-协同prmt5抑制剂
EP4304720A1 (en) * 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors

Also Published As

Publication number Publication date
EP4493555A4 (en) 2026-03-25
CN118871432A (zh) 2024-10-29
WO2023174250A1 (en) 2023-09-21
US20250000854A1 (en) 2025-01-02
EP4493555A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP7637459B2 (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
WO2022206723A1 (zh) 杂环类衍生物、其制备方法及其医药上的用途
JP6034877B2 (ja) Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
RU2701517C2 (ru) Производные хиназолинона, применимые в качестве модуляторов fgfr киназы
CN116162099A (zh) 杂环类衍生物及其制备方法和用途
CN102906090B (zh) 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
TWI438193B (zh) 醯基硫脲化合物或其鹽、及其用途
US20250000854A1 (en) 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
JP2020510642A (ja) ｏ−アミノヘテロアリールアルキニル基含有化合物およびその製造方法と用途
KR20070107104A (ko) Ｒａｆ 억제제 화합물 및 방법
TW201400486A (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒□衍生物
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
WO2022206724A1 (zh) 杂环类衍生物及其制备方法和用途
CN103402995B (zh) 吲哚、吲唑衍生物或其盐
WO2022227987A1 (zh) 杂环类衍生物及其制备方法和用途
WO2024099402A1 (en) Intermediates and process of compounds for the degradation of egfr kinase
WO2025068985A1 (en) 1-(1-oxo-1,2-dihydrophthalazin-6-yl)cycloalkyl-1-carboxamide derivatives as mta-cooperative inhibitors of prmt5
CN119707931A (zh) 作为prmt5的mta协同抑制剂的1-(1-氧代-1,2-二氢酞嗪-6-基)环烷基-1-甲酰胺衍生物的中间体和合成方法
WO2024245430A1 (en) Compounds for the degradation of egfr kinase
JP2024528073A (ja) 有機ピリジン－ピラゾール化合物及びその使用
CN116332960A (zh) 一种哒嗪类化合物、其药物组合物及应用
KR20250121036A (ko) 나프타미드계 화합물, 이의 제조방법 및 응용
JP2026506342A (ja) ＰＲＭＴ５のＭＴＡ協働阻害剤としての５－アミノ－１Ｈ－ピロロ［３，２－ｂ］ピリジン－２－カルボキサミド誘導体

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260309